Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer

Jiayun Zhong,1 Yu Liu,2 Qian Fu,1 Dan Huang,2 Wenjun Gong,2 Jian Zou2 1Department of Pharmaceutical, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republic of China; 2Department of Clinical Pharmacy, the People’s Hospital of Pengzhou, Chengdu, Sichuan, 611930, People’s Republ...

Full description

Bibliographic Details

Published in:	Cancer Management and Research
Main Authors:	Zhong J, Liu Y, Fu Q, Huang D, Gong W, Zou J
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-06-01
Subjects:	regorafenib metastatic colorectal cancer cost-effectiveness incremental cost-effectiveness ratios
Online Access:	https://www.dovepress.com/cost-effectiveness-analysis-of-regorafenib-versus-other-third-line-tre-peer-reviewed-fulltext-article-CMAR